Drug Monograph

Drug/Drug Class:	**Morphabond ER® (morphine sulfate) extended release tablet/ Long Acting Opioids**
Prepared for:	MO HealthNet
Prepared by:	Conduent-Heritage

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Morphabond ER® is available in an extended release tablet containing 15 mg, 30 mg, 60 mg, or 100 mg of morphine sulfate respectively.
Manufacturer:	Daiichi Sankyo, Inc., Parsippany, NJ 07054
Indications:	Morphabond ER® is indicated for the management of pain severe enough to require daily, around the clock, long term opioid treatment and for which alternative treatment options are inadequate.
Costs:	$5.40 per 15 mg tablet, $10.80 per 30 mg tablet, $16.98 per 60 mg tablet, and $28.30 per 100 mg tablet of Morphabond ER®. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Under Solicitation ☐ Appropriate Indications ☐ Non Preferred

Prepared By: Luke Boehmer Pharm.D.
Date: August 4, 2017

© 2017 Conduent Business Services, LLC All Rights Reserved.